Interferon Beta-1A Injectable Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 30 mcg, 22 mcg or 44 mcg,125 mcg, 125 mcg, 150 mcg,175 mcg
Reference Brands: Avonex, Rebif, Plegridy(US &EU)
Category:
Multiple sclerosis
Interferon Beta-1a reduces inflammation and modulates immune responses in multiple sclerosis by inhibiting pro-inflammatory cytokines and immune cell activity. It decreases relapse rates, slows disease progression, and reduces lesion development. Benefits include improved neurological function, symptom control, and enhanced quality of life for MS patients.
Interferon Beta-1a injectable is available in Injection
and strengths such as 30 mcg, 22 mcg or 44 mcg,125 mcg, 125 mcg, 150 mcg,175 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Interferon Beta-1a injectable is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Interferon Beta-1a injectable can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Interferon Beta-1a, marketed as Avonex, Rebif, and Plegridy, is approved in the US by the FDA and in the EU via EMA for multiple sclerosis treatment. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. In the US, FDA review involves detailed analysis of clinical trial results and manufacturing processes, while the EU ensures compliance with regional standards.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing